Patents by Inventor Andrew Turner

Andrew Turner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

MODIFIED TRANSFERIN-ANTIBODY FUSION PROTEINS

Publication number: 20080220002

Abstract: Modified fission proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

Type: Application

Filed: April 3, 2007

Publication date: September 11, 2008

Inventors: Homayoun Sadeghi, Christopher P. Prior, Andrew Turner
Cosmetic compositions

Patent number: 7329403

Abstract: Cosmetic compositions in the form of soft solids having in combination an improved resistance to syneresis and retained efficacy and which contain a particulate antiperspirant suspended in a water-immiscible carrier liquid structured by a structurant system are obtainable by employing as carrier liquid a mixture of a hydrocarbon oil and an aromatic ester oil in a weight ratio of from 1:2 to 15:1 and as structurant system from 5.5 to 20% in total of a di or triblock alkylene/arylene block copolymer and an organic wax in a weight ratio to each other of from 5:1 to 30:1.

Type: Grant

Filed: June 25, 2003

Date of Patent: February 12, 2008

Assignee: Unilever Home & Personal Care USA Division of Conopco, Inc.

Inventors: Beng Sim Chuah, Bruce Steven Emslie, Kevin Ronald Franklin, Daniel Albert Martindale, Graham Andrew Turner
Optical Fibre Ah Ment Apparatus And Method

Publication number: 20080018896

Abstract: A method of coupling a first optical beam into the first end of an optical fibre is described that comprises the steps of (i) coupling light into the second end of the optical fibre such that an optical reference beam is output from the first end of the optical fibre and (ii) matching at least one beam parameter of the first optical beam with the corresponding beam parameter of the optical reference beam (10). Step (ii) may be performed using a wavefront sensor. Corresponding apparatus is additionally described.

Type: Application

Filed: July 7, 2005

Publication date: January 24, 2008

Inventors: Andrew Scott, Andrew Turner
Albumin fusion proteins

Publication number: 20070287173

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Type: Application

Filed: March 14, 2005

Publication date: December 13, 2007

Inventors: Craig Rosen, Homayoun Sadeghi, Christopher Prior, Andrew Turner
Epo Mimetic Peptides and Fusion Proteins

Publication number: 20070275871

Abstract: EPM peptides, including EPM peptide-fusion proteins with increased serum half-life or serum stability are disclosed. Compositions comprising the EPM peptides or fusion proteins and methods of treating or preventing disorders by administering a therapeutically or prophylactically effective amount of an EPM peptide or fusion protein to a patient in need thereof are also disclosed.

Type: Application

Filed: August 30, 2004

Publication date: November 29, 2007

Applicant: BIOREXIS TECHNOLOGY, INC.

Inventors: Homayoun Sadeghi, Andrew Turner
Albumin fusion proteins

Publication number: 20070259815

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Type: Application

Filed: April 9, 2007

Publication date: November 8, 2007

Applicants: Human Genome Sciences, Inc., Delta Biotechnology Limited

Inventors: Craig Rosen, William Haseltine, David Ballance, Andrew Turner, Steven Ruben
Precious Metal Recovery

Publication number: 20070227903

Abstract: Precious metals can be selectively removed from a solution containing an excess of base metals by electrolysis in a divided cell. This necessitates controlling the pH of the solution, and controlling the voltage applied to the electrodes, such that precious metals are deposited preferentially on the electrode in contact with the solution. For example the precious metals may be deposited selectively onto an anode, presumably with formation of a hydrous oxide, if the pH is held at say less than pH 1.0 and the cell voltage held less than 1.3 V.

Type: Application

Filed: April 4, 2005

Publication date: October 4, 2007

Inventors: Andrew Turner, Francisco Del Campo, Malcolm Adam
Metal implants

Publication number: 20070181221

Abstract: A metal implant for use in a surgical procedure is provided with a surface layer that is integral with the metal substrate, and which incorporates a biocidal material. The surface layer is grown by anodising at a voltage between 50 and 150 V, and the biocidal material incorporated in it by ion exchange. This produces a significantly harder surface than anodising at low voltage, and generates pits containing ion-absorbing material.

Type: Application

Filed: March 3, 2005

Publication date: August 9, 2007

Inventors: Martin Pickford, David Lewis, Andrew Turner
Recovery process

Publication number: 20070114134

Abstract: The present invention provides a process for the recovery of radiolabelled isotopes from organic substances labelled or contaminated with one or more radiolabelled isotopes, which process comprises: i) adding organic substances labelled or contaminated with a radiolabelled isotope to an acidic aqueous electrolyte containing silver ions as an electrochemically regenerable primary oxidising species; ii) subjecting the acidic aqueous electrolyte to an electric potential; and iii) recovering the radiolabelled isotope from the products of the electrochemical process resulting from the application of the electric potential; wherein the process is carried out at a slight pressure depression.

Type: Application

Filed: May 9, 2003

Publication date: May 24, 2007

Inventors: Stuart Legg, Christopher Jones, Andrew Turner
Quinazoline derivatives

Publication number: 20070099943

Abstract: The invention concerns quinazoline derivatives of Formula I wherein R1 and R2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB, particularly EGF, receptor tyrosine kinases.

Type: Application

Filed: December 11, 2006

Publication date: May 3, 2007

Inventors: Robert Bradbury, Jason Kettle, James McCabe, Andrew Turner, Laurent Hennequin
Modified transferrin fusion proteins

Publication number: 20070066813

Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

Type: Application

Filed: August 28, 2003

Publication date: March 22, 2007

Inventors: Christopher Prior, Char-Huei Lai, Homayoun Sadeghi, Andrew Turner
Modified transferrin fusion proteins

Publication number: 20070050855

Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

Type: Application

Filed: August 15, 2006

Publication date: March 1, 2007

Inventors: Christopher Prior, Char-Huei Lai, Homayoun Sadeghi, Andrew Turner
Modified transferin-antibody fusion proteins

Publication number: 20070031440

Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

Type: Application

Filed: August 28, 2003

Publication date: February 8, 2007

Inventors: Christopher Prior, Homayoun Sadeghi, Andrew Turner
Quinazoline derivatives

Patent number: 7148230

Abstract: The invention concerns quinazoline derivatives of Formula I wherein R1 and R2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB, particularly EGF, receptor tyrosine kinases.

Type: Grant

Filed: June 1, 2004

Date of Patent: December 12, 2006

Assignee: AstraZeneca AB

Inventors: Robert Hugh Bradbury, Jason Grant Kettle, James McCabe, Andrew Turner, Laurent Francois Andre Hennequin
Detector array and cross-talk linearity connection

Publication number: 20060202124

Abstract: An infrared imaging microscope, particularly of the type used to carry out FT-IR measurement, including a detector in the form of a relatively small detector array of individual detector elements. The outputs of the detector elements are fed in parallel to an electronic circuit for processing. The relatively small array allows the outputs to be processed without need for multiplexing thereby avoiding reduction in signal-to-noise. The detector array may substantially range from about 3 to about 100 detector elements, and is preferably in a range from about 16 to about 64 detector elements.

Type: Application

Filed: February 1, 2006

Publication date: September 14, 2006

Inventors: Robert Hoult, Andrew Turner
Modified transferrin fusion proteins

Publication number: 20060205037

Abstract: Modified fusion proteins of a transferrini moiety, a GLP-1 moiety and a linker moiety, with increased productivity, bioactivity and serum half-life are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation. The fusion proteins of the invention are useful for the treatment of Type 2 diabetes, Type 1 diabetes, obesity, congestive heart failure, and non-fatty liver disease.

Type: Application

Filed: March 6, 2006

Publication date: September 14, 2006

Inventors: Homayoun Sadeghi, Andrew Turner, Christopher Prior, David Ballance
Albumin fusion proteins

Publication number: 20060194735

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

Type: Application

Filed: May 8, 2006

Publication date: August 31, 2006

Applicants: Human Genome Sciences, Inc., Delta Biotechnology Limited

Inventors: Craig Rosen, William Haseltine, David Ballance, Andrew Turner, Steven Ruben
Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains

Publication number: 20060130158

Abstract: Fusion proteins of transferrin and other therapeutic moieties with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

Type: Application

Filed: August 28, 2003

Publication date: June 15, 2006

Inventors: Andrew Turner, Homayoun Sadeghi
CROSS-TALK LINEARITY CONNECTION

Publication number: 20060114127

Abstract: An array of photoconductive elements comprises an array of radiation detectors; an electrical lead connected to the array of radiation detectors; at least one amplifier receptive of an output signal of the array of radiation detectors; a summation device receptive of an output signal of the at least one amplifier; and a positive feedback loop for reducing crosstalk by directing an output signal of the summation device to the at least one amplifier. A circuit processes the outputs of the array of radiation detectors. The photoconductive elements may be operated in a constant voltage mode or a constant current mode.

Type: Application

Filed: January 12, 2006

Publication date: June 1, 2006

Inventor: Andrew Turner
Transferrin fusion proteins libraries

Publication number: 20060105387

Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

Type: Application

Filed: August 28, 2003

Publication date: May 18, 2006

Inventors: Christopher Prior, Andrew Turner, Homayoun Sadeghi

prev … 5 6 7 8 9 10 11 next